CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
Nature Medicine2017Vol. 24(1), pp. 20–28
Citations Over TimeTop 1% of 2017 papers
Terry J. Fry, Nirali N. Shah, Rimas J. Orentas, Maryalice Stetler‐Stevenson, Constance M. Yuan, Sneha Ramakrishna, Pamela L. Wolters, Staci Martin, Cindy Delbrook, Bonnie Yates, Haneen Shalabi, Thomas J. Fountaine, Jack F. Shern, Robbie G. Majzner, David F. Stroncek, Marianna Sabatino, Yang Feng, Dimiter S. Dimitrov, Ling Zhang, Sang M. Nguyen, Haiying Qin, Boro Dropulić, Daniel W Lee, Crystal L. Mackall
Related Papers
- → 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors(2015)1,752 cited
- → Modulation of B Lymphocyte Antigen Receptor Signal Transduction by a CD19/CD22 Regulatory Loop(1999)135 cited
- → Activation of B lymphocytes: integrating signals from CD19, CD22 and FcγRIIb1(1996)68 cited
- Functional evaluation of CD19- and CD22-negative variants of B-lymphoid cell lines.(1988)
- → Tinkering in the garage — tuning CARs for safety(2019)